Publications by authors named "D H Josephs"
Aims: This national study investigated hospital quality and patient factors associated with treatment location for systemic anticancer treatment (SACT) in patients with metastatic cancers.
Materials And Methods: Using linked administrative datasets from the English NHS, we identified all patients diagnosed with metastatic breast and bowel cancer between 1 January 2016 and 31 December 2018, who subsequently received SACT within 4 months from diagnosis. The extent to which patients bypassed their nearest hospital was investigated using a geographic information system (ArcGIS).
Purpose: The Graham Roberts Study was initiated in 2018 and is the first Trials Within Cohorts (TwiCs) study for bladder cancer. Its purpose is to provide an infrastructure for answering a breadth of research questions, including clinical, mechanistic, and supportive care centred questions for bladder cancer patients.
Participants: All consented patients are those aged 18 or older, able to provide signed informedconsent and have a diagnosis of new or recurrent bladder cancer.
Article Synopsis
- - A Phase I trial tested the safety and tolerability of MOv18 IgE, a new type of chimeric IgE antibody, in cancer patients whose tumors express folate receptor-alpha, with a focus on minimizing allergic reactions.
- - The study involved dose escalation from 70 μg to 12 mg, using skin prick and basophil activation tests to identify low-risk patients; the main side effect noted was temporary hives, with one case of anaphylaxis linked to pre-existing reactive basophils.
- - Results indicate that MOv18 IgE therapy is tolerable and shows potential anti-tumor activity, evidenced by a positive response in a patient with ovarian cancer, suggesting that IgE-based
Article Synopsis
- Despite existing checkpoint inhibitor therapies, about half of melanoma patients still struggle with poor outcomes.
- A new engineered monoclonal IgE antibody targeting the CSPG4 antigen shows promise by binding to melanoma cells and enhancing immune responses.
- In studies, this IgE therapy significantly improved survival and anti-tumor activity in models, suggesting its potential as an effective treatment option for melanoma patients.